<unk>  should not be used in men with moderate to severe hepatic impairment and in those receiving CYP3A4 inhibitors such as ketoconazole, ritonavir, and telithromycin.<unk>  also cannot be used in patients with heart failure, permanent pacemaker, or other significant ischemic heart disease. Caution is advised in men receiving thioridazine, monoamine oxidase inhibitors, SSRIs, serotonin-norepinephrine reuptake inhibitors, or tricyclic antidepressants. If a patient stops taking one of these drugs, he should wait for 14 days before taking<unk> . If a patient stops taking<unk> , he should wait for 7 days before receiving these drugs.
Dapoxetine
Atomoxetine
Duloxetine
Edivoxetine
Vortioxetine
Fluoxetine
Nabilone
Guanfacine